rs199473680
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_025099.6(CTC1):c.3019delC(p.Leu1007CysfsTer62) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000161 in 1,613,124 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_025099.6 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000112 AC: 17AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000189 AC: 47AN: 248864Hom.: 0 AF XY: 0.000163 AC XY: 22AN XY: 135030
GnomAD4 exome AF: 0.000166 AC: 243AN: 1460886Hom.: 0 Cov.: 31 AF XY: 0.000160 AC XY: 116AN XY: 726838
GnomAD4 genome AF: 0.000112 AC: 17AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74386
ClinVar
Submissions by phenotype
Cerebroretinal microangiopathy with calcifications and cysts 1 Pathogenic:4
- -
- -
- -
Criteria applied: PVS1,PM2_SUP,PS3_SUP,PM3 -
not provided Pathogenic:3
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Published functional studies demonstrate a damaging effect: anomalous telomere replication (Gu et al., 2013); This variant is associated with the following publications: (PMID: 22387016, 23869908, 34308104) -
DNA sequence analysis of the CTC1 gene demonstrated a single base pair deletion in exon 19, c.3019del. This sequence change results in an amino acid frameshift and creates a premature stop codon 61 amino acids downstream of the change, p.Leu1007Cysfs*62. This sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated CTC1 protein with potentially abnormal function. This sequence change has been described in the gnomAD database with a frequency of 0.11% in the Finnish subpopulation and 0.019% in the overall population (dbSNP rs199473680). This pathogenic sequence change has previously been described in the compound heterozygous state in an individual with cerebroretinal microangiopathy with calcifications and cysts (PMID: 22387016). A functional study in mouse cDNA indicates that this sequence change causes loss-of-function (PMID: 23869908). These collective evidences indicate that this sequence change is pathogenic. This pathogenic sequence change in the heterozygous state is not sufficient to cause this individual’s phenotype. -
- -
Coats plus syndrome Pathogenic:1
The p.Leu1007CysfsX62 variant in CTC1 has been reported in 1 compound heterozygous, Finnish individual with clinical features of cerebroretinal microangiopathy with calcifications and cysts-1 (CRMCC1) (Polvi 2012). This variant has also been identified in 0.02% (13/66568) of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs199473680). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1007 and leads to a premature termination codon 62 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. In vitro and mouse model functional studies also provide evidence that the p.Leu1007CysfsX62 variant impacts protein function (Gu 2013). No individuals affected with CRMCC1 reported to date are compound heterozygous or homozygous for 2 null variants, suggesting that biallelic null mutations might be incompatible with development (Anderson 2012). In summary, this variant meets criteria to be classified as pathogenic for CRMCC1 in an autosomal recessive manner based upon case observation, functional evidence and low frequency in controls. -
CTC1-related disorder Pathogenic:1
The CTC1 c.3019delC variant is predicted to result in a frameshift and premature protein termination (p.Leu1007Cysfs*62). This variant has been reported in the compound heterozygous state in an individual with cerebroretinal microangiopathy with calcifications and cysts (CRMCC), while the patient’s heterozygous father was unaffected (Polvi et al. 2012. PubMed ID: 22387016). Functional studies of mouse CTC1 p.L1002*, which is the equivalent to human CTC1 p.Leu1007Cysfs*62, showed that the variant lead to a disruption of CST complex formation, which is necessary for telomere replication (Gu et al. 2013. PubMed ID: 23869908). This variant is reported in 0.11% of alleles in individuals of European (Finnish) descent in gnomAD. Frameshift variants in CTC1 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Dyskeratosis congenita Pathogenic:1
This sequence change creates a premature translational stop signal (p.Leu1007Cysfs*62) in the CTC1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTC1 are known to be pathogenic (PMID: 22267198, 22387016). This variant is present in population databases (rs199473680, gnomAD 0.1%). This premature translational stop signal has been observed in individual(s) with cerebroretinal microangiopathy with calcifications and cysts (PMID: 22387016). ClinVar contains an entry for this variant (Variation ID: 843472). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at